Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Buy" from Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given an average recommendation of "Buy" by the six analysts that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $20.20.

Several research analysts have issued reports on LXEO shares. Leerink Partners dropped their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Monday, March 24th. Chardan Capital dropped their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. HC Wainwright dropped their price objective on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Finally, Royal Bank of Canada dropped their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th.

Lexeo Therapeutics Stock Performance

LXEO stock traded down $0.12 during midday trading on Thursday, hitting $2.70. The stock had a trading volume of 2,050,072 shares, compared to its average volume of 497,214. The firm has a market capitalization of $89.63 million, a price-to-earnings ratio of -0.85 and a beta of 1.27. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $19.50. The stock has a 50-day simple moving average of $3.08 and a 200 day simple moving average of $4.70. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). As a group, equities research analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LXEO. Affinity Asset Advisors LLC acquired a new stake in shares of Lexeo Therapeutics in the first quarter valued at $5,139,000. Millennium Management LLC increased its stake in shares of Lexeo Therapeutics by 654.8% in the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock valued at $3,718,000 after buying an additional 929,538 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Lexeo Therapeutics by 15.3% in the fourth quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock valued at $28,508,000 after buying an additional 576,059 shares in the last quarter. Altium Capital Management LLC acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at $2,665,000. Finally, Point72 Asset Management L.P. increased its stake in shares of Lexeo Therapeutics by 102.5% in the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock valued at $4,937,000 after buying an additional 379,828 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.